We repurpose drugs for some the world’s most challenging medical conditions.
We are passionate about helping transform healthcare. It’s what drives us to do our best – every day.
It takes a team of dedicated, seasoned professionals with a deep understanding of intricacies of drug development to find opportunities where others see none, to tackle the toughest of diseases and conditions, to push to find a novel way forward, because lives are depending on it.
Vision. Courage. Compassion. We aspire to embody these values in everything we do.
We’re EMBARK HEALTHCARE.
Implementation of a successful [drug repurposing] strategy is not a simple undertaking. The skills and expertise required are considerable and range across a number of different disciplines. They include the need to access compounds and information, determine the disease area of focus and implement a well thought-through business and IP strategy.
The successful execution of a [drug repurposing] business model can result in a pipeline that has an increased number of Phase II-level compounds, as well as lead to new innovations in disease etiology and pathway/network biology.
Source: Therapeutic Drug Discovery, Drug Discovery World
Embark's Founding Partners
David M. Geliebter has over 50 years of experience successfully starting and growing businesses. He was a founding principal and President of Evolution Capital, a healthcare investment banking firm. David is the Managing Partner of Embark Healthcare (formerly Carrot Capital). David is Executive Chairman of Embark’s family of companies. He is a past winner of the Ernst & Young Entrepreneur of the Year Award.
Sven M. Jacobson, MBA, has over 20 years of senior management experience. He is the Managing Partner of Embark Healthcare. Sven is CEO of Embark’s family of companies. He received his Bachelor of Science Engineering (BSc Eng) and MBA degrees from the University of the Witwatersrand in Johannesburg, South Africa.
The Core Team
Thomas W. MacAllister, JD, PhD, is licensed IP attorney and a pharmaceutical executive with a PhD in molecular biology. He has over 25 years of experience in pharma. Tom is currently VP of Research and Development, and General Counsel for Embark’s family of companies.
Ann C. Tunstall, PhD, has worked as a regulatory and clinical professional in the healthcare industry for more than 25 years. Ann is Vice President of Regulatory and Clinical Operations for Embark’s family of companies. She has a Ph.D. in Biomedical Engineering from the University of Texas Southwestern Medical Center, an M.S. in Material Science from Duke University, and a B.S. in Biomedical Engineering from Duke University.
Roland Gerritsen van der Hoop, MD, PhD, is a pharmaceutical executive with over 30 years of experience. Roland is Chief Medical Officer of Embark’s family of companies. He has an MD and PhD from Utrecht University, the Netherlands.
Ibrahim Mian, MD, Director of Operations, brings almost a decade of clinical experience, taking care of patients from all age groups in diverse populations. He has an MD from Wake Forest University School of Medicine and a B.S. in Biology from Duke University.
Oscar Liu, PhD, has been working in the pharmaceutical industry for over 20 years with increasing responsibilities. Oscar has led CMC development for multiple NDA and ANDA approvals. He has Ph.D. from Duke University, M.S. from SUNY-Binghamton, and B.S. from Xiamen University. Oscar is Manager of CMC for Embark’s family of companies.
Amy Kreit has over 30 years of diverse accounting experience from startups to Fortune 500 companies. She has a B.S. in Accounting from Syracuse University. Amy is Finance Manager for Embark’s family of companies.
Enda Anatole holds a B.A. in Human Resource Management from the Zicklin School of Business at Baruch College. Enda is Office Assistant for Embark’s family of companies.